Semler Scientific ($NASDAQ:SMLR) declared its financial performance for the fiscal quarter that ended on June 30 2023, on August 10 2023. The total revenue was USD 18.6 million, signifying a 25.4% growth from the same period in the preceding fiscal year. Net income rose to USD 5.9 million, a 44.5% increase compared to the same quarter in the previous year.
SEMLER SCIENTIFIC, a leading provider of medical diagnostic products and services, reported its second-quarter earnings for the fiscal year 2023 on Thursday, August 10th. The stock opened at $23.7 and closed at $23.5, a 0.8% drop from its prior closing price of 23.7. This decrease in costs was attributed to the company’s focus on reducing their operating costs to remain competitive in the industry. Overall, SEMLER SCIENTIFIC’s second-quarter earnings were slightly below expectations, but still showed that the company is making progress in improving their financial performance and remains competitive in the medical diagnostic industry. Live Quote…
About the Company
Ownership (Institutional/ Fund Holdings)
Below shows the total revenue, net income and net margin for Semler Scientific. More…
Income Statement Reports (Yearly/ Quarterly/ LTM)
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Semler Scientific. More…
Cash Flow Statement (Yearly/ Quarterly/ LTM)
Cash Flow Supplement
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Semler Scientific. More…
Balance Sheet (Yearly/ Quarterly)
Balance Sheet Supplement
||Book Value Per Share
Key Ratios Snapshot
Some of the financial key ratios for Semler Scientific are shown below. More…
Income Statement Ratios
Balance Sheet Ratios
Cash Flow Ratios
Other Supplementary Items
|3Y Rev Growth
||3Y Operating Profit Growth
GoodWhale has conducted an analysis of SEMLER SCIENTIFIC‘s financials and come to the conclusion that it has a high health score of 10/10, considering its cashflows and debt. This indicates that it is capable of sustaining future operations in times of crisis. Upon further analysis, we have classified SEMLER SCIENTIFIC as a ‘gorilla’ type of company, one that has achieved stable and high revenue or earning growth due to its strong competitive advantage. Given these characteristics, we believe that investors who are interested in stable growth and competitive advantage should consider investing in SEMLER SCIENTIFIC. Although the company does not offer a high dividend, it is strong in asset growth, profitability, and has a strong competitive edge. These factors make it an attractive option for investors who want to benefit from long-term growth. More…
Risk Rating Analysis
Star Chart Analysis
The Company operates through two segments: Semler and Quidel. Semler provides personalized medicine products and services to help physicians and other healthcare providers improve patient care and reduce costs. Quidel provides diagnostic solutions, including molecular diagnostics, rapid diagnostic tests, and immunoassays.
– Rapid Micro Biosystems Inc ($NASDAQ:RPID)
The company’s market cap is $104.86 million and its ROE is -20.93%. The company develops and manufactures rapid microbiological testing products for use in the pharmaceutical, biotechnology, food, and cosmetics industries. Its products include the Growth Direct System, a rapid automated microorganism detection and enumeration system; the AquaSnap Total aerobic Count Test, a water testing system; and the Compendial Counts Test, a method for enumerating aerobic microorganisms in food and cosmetics.
– Applied BioCode Corp ($TWSE:6598)
Applied BioCode, Inc. is a molecular diagnostics company, which focuses on the development and commercialization of multiplex molecular solutions that simplify and improve the diagnosis of infectious diseases and cancer. Its products include BioCode MDx, a multiplex molecular diagnostic platform that can be used for the simultaneous detection and identification of multiple pathogens from a single patient specimen; and Respiratory Pathogen Panel, a multiplexed molecular diagnostic test that detects and identifies common viral and bacterial respiratory pathogens. The company was founded by David J. Wilson, Bruce A. Weintraub, and Gerald V. Niedzwiecki in 2000 and is headquartered in Carlsbad, CA.
As of 2022, Sinocare Inc has a market cap of 20.82B and a Return on Equity of 7.01%. The company is a leading provider of diabetes management products and services in China.
SEMLER SCIENTIFIC reported strong financial results for the second quarter of FY2023, with total revenue increasing 25.4% year-on-year to USD 18.6 million and net income up 44.5%. The company’s impressive growth metrics demonstrate its strong fundamentals and make it an attractive opportunity for investors. Its healthy balance sheet, low debt levels, and attractive valuation make it a lucrative investment proposition. Going forward, SEMLER SCIENTIFIC is well-positioned to capitalize on further growth opportunities and should be watched closely by potential investors.